ASSESSING THE EFFICACY OF PACLITAXEL AND OLAPARIB IN COMPARISON TO PACLITAXEL / CARBOPLATIN FOLLOWED BY EPIRUBICIN/CYCLOPHOSPHAMIDE AS NEOADJUVANT CHEMOTHERAPY IN PATIENTS WITH HER2-NEGATIVE EARLY BREAST CANCER AND HOMOLOGOUS RECOMBINATION DEFICIENCY: